Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset

CHICAGO — Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced rectal cancer, phase 2 study results showed.Longer follow-up is needed to examine the duration of treatment response in this patient population, according to researchers of the study, reported at ASCO Annual Meeting published simultaneously in The New England Journal of Medicine.“Patients with mismatch repair-deficient, locally advanced rectal cancer are treated with standard-of-careRead More

Related Articles